Unitedhealth Group Inc

• Natera reported strong adoption for Signatera and positive Medicare reimbursement updates. • The company achieved robust top-line revenue growth with $2.31B annual revenue. • Analysts issued Buy ratings with an average price target of $342.35.

• Danaher reaffirmed its third-quarter and full-year financial guidance. • Julie Sawyer Montgomery will assume the CEO role on October 1. • Danaher reports annual revenue of $24.57B and net profit of $3.61B.

• UBS upgraded Illumina to Buy with a price target of $260. • Illumina will rejoin the S&P 500 index from the S&P MidCap 400. • The company reported strong NovaSeq X demand and consecutive earnings beats.

• Thermo Fisher shares rose following positive management commentary at the healthcare conference. • Executive leadership highlighted recovering client spending in biopharma and life sciences. • The company reported $44.56B in annual revenue and $6.70B in net profit.

• RBC Capital Markets upgraded ResMed to Outperform, raising its price target. • ResMed launched an accelerated share repurchase program funded by MatrixCare divestiture proceeds. • Strong global device revenue and competitor regulatory disruptions supported market share momentum.

• Cooper Companies missed revenue expectations and lowered its fiscal guidance. • The board decided to retain the CooperSurgical business. • Multiple analysts downgraded the stock following negative market reactions.